Inhibikase TherapeuticsIKT
13F holders, Q2 2025 (June 30)48holders +1
24new positions
23sold out
$1.95avg. 13F price*
At the end of Q2 2025, 48 institutions reported holding Inhibikase Therapeutics Inc. (IKT) in their 13F filings, up 1 from Q1 2025. 24 opened new positions and 23 sold out. The largest holders were Sands Capital Alternatives, LLC ($21.4M), Soleus Capital Management, L.P. ($12.3M) and Fairmount Funds Management LLC ($11.9M).
- Company
- Inhibikase Therapeutics Inc.
- CUSIP
- 45719W205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 24 | $1.7M |
| Exits | 23 | $4.1M |
All 13F filers, Q1 2025 → Q2 2025: 5,745,171 shares bought and 2,695,547 shares sold, net +3,049,624 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 48 holders
| Sands Capital Alternatives, LLC | 4.20% | No change | 10,950,000 | $21.4M |
| Soleus Capital Management, L.P. | 0.85% | No change | 6,325,000 | $12.3M |
| Fairmount Funds Management LLC | 1.55% | No change | 6,125,000 | $11.9M |
| Perceptive Advisors LLC | 0.40% | Reduce -8.3% | 5,432,293 | $10.6M |
| Commodore Capital LP | 0.74% | Add +1.0% | 5,397,488 | $10.5M |
| ADAR1 Capital Management, LLC | 1.64% | No change | 5,122,105 | $10.0M |
| Vanguard Group Inc. | 0.00% | Add +13.2% | 3,224,370 | $6.3M |
| BlackRock, Inc. | 0.00% | Add +543.5% | 2,728,168 | $5.3M |
| Blackstone Inc. | 0.02% | Add +27.4% | 2,638,276 | $5.1M |
| Nantahala Capital Management, LLC | 0.30% | No change | 2,190,000 | $4.3M |
| Geode Capital Management, LLC | 0.00% | Add +228.5% | 1,066,700 | $2.1M |
| Stonepine Capital Management, LLC | 1.41% | Reduce -19.8% | 733,793 | $1.4M |
| State Street Corp. | 0.00% | Add +849.8% | 397,812 | $776K |
| Northern Trust Corp. | 0.00% | Add +513.5% | 392,716 | $766K |
| Susquehanna International Group, LLP | 0.00% | Reduce -24.1% | 383,071 | $747K |
| Blair William & Co. | 0.00% | Add +0.6% | 156,953 | $306K |
| Charles Schwab Investment Management Inc. | 0.00% | New | 152,298 | $297K |
| FMR LLC | 0.00% | New | 144,239 | $281K |
| Bank of New York Mellon Corp | 0.00% | New | 132,473 | $258K |
| Barclays PLC | 0.00% | Add +31.3% | 110,252 | $215K |
| Morgan Stanley | 0.00% | Add +360.5% | 99,678 | $194K |
| Nuveen, LLC | 0.00% | New | 78,659 | $153K |
| New York State Common Retirement Fund | 0.00% | New | 60,700 | $118K |
| Rhumbline Advisers | 0.00% | New | 58,524 | $114K |
| UBS Group AG | 0.00% | Reduce -14.6% | 38,674 | $75K |
| Wells Fargo & Company | 0.00% | Add +22849.7% | 38,326 | $75K |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.00% | New | 33,023 | $64K |
| Intech Investment Management LLC | 0.00% | New | 31,406 | $61K |
| LMR Partners LLP | 0.00% | No change | 31,092 | $61K |
| T. Rowe Price Associates Inc. | 0.00% | New | 30,606 | $60K |
| Invesco Ltd. | 0.00% | New | 30,712 | $60K |
| JPMorgan Chase & Co. | 0.00% | New | 28,579 | $56K |
| Citigroup Inc. | 0.00% | Reduce -20.9% | 20,393 | $40K |
| Bank of America Corp. | 0.00% | Reduce -57.3% | 19,216 | $37K |
| Voya Investment Management LLC | 0.00% | New | 18,755 | $37K |
| Police & Firemen's Retirement System of New Jersey | 0.00% | New | 17,638 | $34K |
| Caxton Corp. | 0.32% | No change | 16,393 | $32K |
| ProShare Advisors LLC | 0.00% | New | 12,401 | $24K |
| Focus Partners Advisor Solutions, LLC | 0.00% | New | 10,708 | $21K |
| BNP Paribas Financial Markets | 0.00% | New | 9,182 | $18K |
| Ameritas Investment Partners, Inc. | 0.00% | New | 6,174 | $12K |
| Legal & General Group Plc | 0.00% | New | 5,504 | $11K |
| Royal Bank of Canada | 0.00% | New | 4,587 | $10K |
| California State Teachers Retirement System | 0.00% | New | 3,773 | $7K |
| Amalgamated Bank | 0.00% | New | 2,065 | $4K |
| Sterling Capital Management LLC | 0.00% | New | 1,505 | $3K |
| Raymond James Financial Inc. | 0.00% | New | 1,000 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 100 | $195 |
"% of holder's portfolio" is IKT's weight in each manager's 13F, not the share of Inhibikase Therapeutics Inc. the manager owns.